Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Eco-Friendly Immunoassay Reagents Featured at AACC 2015

By LabMedica International staff writers
Posted on 29 Jul 2015
A pioneering eco-friendly product line of unique, high quality immunoassay reagents that contains no toxic biological or chemical hazards are being exhibited at the 2015 AACC Meeting & Clinical Lab Expo (July 26–30; Atlanta, GA, USA), in Booth 4017.

ECO-TEK, the only commercially available line of environmentally safe immunoassay reagents, will be featured at AACC by Kem-En-Tec Diagnostics A/S (Taastrup, Denmark) and its US distributor, Rainbow Scientific, Inc. More...
(Windsor, CT, USA). Kem-En-Tec Diagnostics, a pioneer of safe and environmentally friendly immunoassay reagents that maintain high standards in quality, sensitivity, and shelf-life, develops ECO-TEK products to eliminate biological and chemical hazards such as BSA, sodium azide, and harmful organic solvents still commonly found in diagnostic assay components.

ECO-TEK reagents reduce the environmental impact of ELISA, blotting, or IHC applications without compromising reliability or stability. Additionally, Kem-En-Tec’s innovative WellChampion Blocking & Protection Buffer eliminates 2 to 3 steps in ELISA plate production, significantly reducing water waste.

Kem-En-Tec Diagnostics technical experts Henrik Christiansen, president & CEO, and Henny Nielsen, Sales & Marketing manager, will be present at the booth, providing visitors a firsthand opportunity to learn about the benefits of ECO-TEK reagents, especially for ELISA kit development. Visitors will also have an opportunity to arrange for free product samples.

“The latest developments from our R&D team provide enhancements in the dynamic range of TMB substrates and phycoerythrin (PE) labeled conjugates,” said Mr. Christensen, “The AACC offers us a unique chance to communicate our ability to meet the requirements of the immunoassay market to our customers and partners.”

“ECO-TEK products reduce environmental pollution from laboratory reagents, including elimination of mercury-containing waste,” said Peter Mousseau, president of Rainbow Scientific, “Visitors to our AACC booth will have the opportunity to speak to technical experts from Kem-En-Tec to learn about eco-friendly solutions for their labs.”

Kem-En-Tec Diagnostic products are registered and listed with the FDA as Device Class 1: General Purpose Reagents.

Related Links:

Rainbow Scientific
Kem-En-Tec Diagnostics
American Association for Clinical Chemistry



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Automated Clinical Chemistry Analyzer
Envoy 500+
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.